Sugi Predict

Sugi Predict / Compounds / SCHEMBL533717

SCHEMBL533717

SCHEMBL533717

CCCCCCCCCCCCCCCCCCCCCCOc1ccc(N(C)c2ccc(OCCCCCCCCCCCCCCCCCCCCCC)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR5A1 Q13285 1/20 0.61
▸ LTA4H P09960 4/20 0.55
▸ TP53 P04637 2/20 0.54
▸ TSHR P16473 1/20 0.54
▸ PLA2G4B P0C869 1/20 0.53
▸ THRA P10827 1/20 0.53
▸ THRB P10828 1/20 0.53
▸ RARB P10826 3/20 0.50
▸ PTGES O14684 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ NPC1 O15118 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ ALOX15 P16050 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16706016 1.00 NR5A1 (0.61) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL12589626 0.89 PTGES (0.62) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL11000930 0.89 PTGES (0.62) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL11001964 0.89 PTGES (0.62) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL1263398 0.89 PTGES (0.62) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL23302979 0.89 PTGES (0.62) NR5A1LTA4HTP53TSHRPLA2G4B
Hydrochloric Acid SCHEMBL23302958 0.87 PTGES (0.60) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL8936597 0.85 NR5A1 (0.79) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL11095674 0.85 NR5A1 (0.79) NR5A1LTA4HTP53TSHRPLA2G4B
SCHEMBL10943900 0.85 NR5A1 (0.79) NR5A1LTA4HTP53TSHRPLA2G4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3778621-B1 PEPTIDE SYNTHESIS METHOD JITSUBO CO LTD (JP) 2023-08-23 — — EP claimed
EP-3778621-A1 PEPTIDE SYNTHESIS METHOD Jitsubo Co., Ltd. (JP) 2021-02-17 — — EP claimed
US-9353147-B2 Method for producing peptide AJINOMOTO CO., INC. (JP) 2016-05-31 — — US claimed
US-9353148-B2 Method for producing peptide AJINOMOTO CO., INC. (JP) 2016-05-31 — — US claimed
US-9169187-B2 Method of making peptides using diphenylmethane compound AJINOMOTO CO., INC. (JP) 2015-10-27 — — US claimed
US-20140213761-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC (JP) 2014-07-31 — — US claimed
US-8722934-B2 Diphenylmethane compound AJINOMOTO CO., INC. (JP) 2014-05-13 — — US claimed
US-20140088291-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-27 — — US claimed
US-20140080999-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-20 — — US claimed
EP-2415745-A1 DIPHENYLMETHANE COMPOUND Ajinomoto Co., Inc. (JP) 2012-02-08 — — EP claimed
US-20100249374-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2010-09-30 — — US claimed
US-12351601-B2 Method for producing peptide continuously AJINOMOTO CO., INC. (JP) 2025-07-08 — — US disclosed
WO-2025122535-A2 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 — — WO disclosed
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS AMGEN INC. (US) 2025-06-12 — — US disclosed
US-11939404-B2 Method for producing cyclized peptide having intramolecular S-S bond AJINOMOTO CO., INC. (JP) 2024-03-26 — — US disclosed
US-8722934-B2 Diphenylmethane compound AJINOMOTO CO., INC. (JP) 2014-05-13 — — US disclosed
US-20140088291-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-27 — — US disclosed
US-20140080999-A1 METHOD FOR PRODUCING PEPTIDE AJINOMOTO CO., INC. (JP) 2014-03-20 — — US disclosed
EP-2415745-A1 DIPHENYLMETHANE COMPOUND Ajinomoto Co., Inc. (JP) 2012-02-08 — — EP disclosed
US-20100249374-A1 DIPHENYLMETHANE COMPOUND AJINOMOTO CO., INC. (JP) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249374-A1 DIPHENYLMETHANE COMPOUND CCKAR, DNPEP, QPCTL NR5A1 2883/4885LTA4H 763/4885TP53 1289/4885
US-20250188118-A1 LIQUID PHASE PEPTIDE SYNTHESIS METHODS VIP, RNGTT, SSU72 NR5A1 1636/4885LTA4H 1947/4885TP53 1843/4885
US-20140213761-A1 DIPHENYLMETHANE COMPOUND CCKAR, VIP, CCKBR NR5A1 3226/4885LTA4H 754/4885TP53 2202/4885
US-11939404-B2 Method for producing cyclized peptide having intramolecular S-S bond SPPL2B, PTMS, VIP NR5A1 1233/4885LTA4H 3071/4885TP53 1544/4885
US-20140080999-A1 METHOD FOR PRODUCING PEPTIDE VIP, ANPEP, NPPA NR5A1 2972/4885LTA4H 3028/4885TP53 867/4885
US-20140088291-A1 METHOD FOR PRODUCING PEPTIDE ANPEP, NPPA, LNPEP NR5A1 2104/4885LTA4H 3923/4885TP53 793/4885
US-12351601-B2 Method for producing peptide continuously VIP, NPPA, NGLY1 NR5A1 2347/4885LTA4H 1912/4885TP53 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.